Key result
Detection of EWS-FLI1 or EWS-ERG transcripts in peripheral blood preceded clinical tumor progression in 4 patients, and all 3 patients with non-type 1 EWS-FLI1 transcripts died from progression.
Why the study?
Does monitoring EWS-FLI1 or EWS-ERG transcripts in peripheral blood predict clinical progression in patients with Ewing family tumors?
Population
28 patients with Ewing family of tumors undergoing treatment including chemotherapy, radiotherapy, and…
Design
Cohort
Authors
Loading...
May support transcript monitoring to anticipate Ewing tumor progression; hypothesis-generating and needs prospective validation before clinical adoption.
Cohort (n=28)
Does monitoring EWS-FLI1 or EWS-ERG transcripts in peripheral blood predict clinical progression in patients with Ewing family tumors?
Monitoring circulating tumor cells via EWS-FLI1/ERG transcripts in peripheral blood is a sensitive assay that may predict clinical progression in Ewing tumors.
Lozano et al. (1998) conducted a cohort in Ewing family of tumors (n=28). Presence of EWS-FLI1 or EWS-ERG transcripts in peripheral blood vs. Absence of transcripts was evaluated on Clinical status and tumor progression. Detection of EWS-FLI1 or EWS-ERG transcripts in peripheral blood preceded clinical tumor progression in 4 patients, and all 3 patients with non-type 1 EWS-FLI1 transcripts died from progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: